EU clears first drug therapy for rare disease cALD
Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Minoryx Therapeutics
Private
Minoryx Therapeutics is a clinical-stage biotechnology company developing differentiated therapies for X-linked adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. Its lead candidate, leriglitazone, is an oral, brain-penetrant PPAR-γ agonist for cerebral ALD and Friedreich's ataxia.
Company Info
Recent News
CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa.